

PRODUCT INFORMATION



Tpl2 Kinase Inhibitor

Item No. 19710

CAS Registry No.: 871307-18-5

Formal Name: 4-[(3-chloro-4-fluorophenyl)amino]-6-[(3-pyridinylmethyl)amino]-1,7-naphthyridine-3-carbonitrile

Synonyms: c-Cot Kinase Inhibitor, MAP3K8 Kinase Inhibitor, Tumor Progression Locus 2 Kinase Inhibitor

MF: C₂₁H₁₄ClFN₆

FW: 404.8


Purity: ≥95%

UV/Vis.: λ_{max}: 251, 293, 315, 417 nm

Supplied as: A crystalline solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Tpl2 kinase inhibitor is supplied as a crystalline solid. A stock solution may be made by dissolving the Tpl2 kinase inhibitor in the solvent of choice. Tpl2 kinase inhibitor is soluble in organic solvents such as DMSO and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of Tpl2 kinase inhibitor in these solvents is approximately 1 mg/ml.

Tpl2 kinase inhibitor is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, Tpl2 kinase inhibitor should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Tpl2 kinase inhibitor has a solubility of approximately 0.33 mg/ml in a 1:2 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Tpl2 kinase inhibitor is an inhibitor of tumor progression locus 2 (Tpl2; IC₅₀ = 0.05 μM).¹ It is selective for Tpl2 over MEK, p38 MAPK, Src, MK2, and PKC (IC₅₀s = >40, 180, >400, 110, and >400 μM, respectively). Tpl2 kinase inhibitor inhibits LPS-induced TNF-α production in isolated human monocytes and whole blood (IC₅₀s = 0.7 and 8.5 μM, respectively). It enhances differentiation induced by 1,25-dihydroxy vitamin D₃ (calcitriol; Item No. 71820) in HL-60 and U937 leukemia cells when used at a concentration of 5 μM.² Tpl2 kinase inhibitor (5 μM) inhibits the proliferation of KG-1a leukemia cells.³

References

1. Gavrin, L.K., Green, N., Hu, Y., *et al.* Inhibition of Tpl2 kinase and TNF-α production with 1,7-naphthyridine-3-carbonitriles: Synthesis and structure-activity relationships. *Bioorg. Med. Chem. Lett.* **15(23)**, 5288-5292 (2005).
2. Wang, X. and Studzinski, G.P. Expression of MAP3 kinase COT1 is up-regulated by 1,25-dihydroxyvitamin D₃ in parallel with activated c-jun during differentiation of human myeloid leukemia cells. *J. Steroid Biochem. Mol. Biol.* **121(1-2)**, 395-398 (2010).
3. Wang, X., Gocek, E., Novik, V., *et al.* Inhibition of Cot1/Tlp2 oncogene in AML cells reduces ERK5 activation and upregulates p27^{Kip1} concomitant with enhancement of differentiation and cell cycle arrest induced by silibinin and 1,25-dihydroxyvitamin D₃. *Cell Cycle* **9(22)**, 4542-4551 (2010).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/25/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD

ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM